NGM Biopharmaceuticals Gelecekteki Büyüme

Future kriter kontrolleri 2/6

NGM Biopharmaceuticals kazanç ve gelirin sırasıyla yıllık 14.7% ve 57.6% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 20.3% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde -230.7% olacağı tahmin edilmektedir.

Anahtar bilgiler

14.7%

Kazanç büyüme oranı

20.3%

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi	23.7%
Gelir büyüme oranı	57.6%
Gelecekteki özkaynak getirisi	-230.7%
Analist kapsamı	Low
Son güncelleme	12 Mar 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

What NGM Biopharmaceuticals, Inc.'s (NASDAQ:NGM) 32% Share Price Gain Is Not Telling You

Dec 19

We're A Little Worried About NGM Biopharmaceuticals' (NASDAQ:NGM) Cash Burn Rate

Oct 05

Some Analysts Just Cut Their NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Estimates

Aug 09

Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Could Be Quite Risky

Jun 27

NGM Biopharmaceuticals, Inc.'s (NASDAQ:NGM) Business Is Trailing The Industry But Its Shares Aren't

Apr 17

We Think NGM Biopharmaceuticals (NASDAQ:NGM) Needs To Drive Business Growth Carefully

Dec 20

NGM Biopharma sinks ~72% after phase 2 trial of its eye degeneration treatment fails

Oct 17

NGM Biopharmaceuticals appoints CFO Siobhan Nolan Mangini to the additional role of President

Jun 30

NGM Biopharmaceuticals: Eye Disorder Data Due Second Half Of 2022

Jun 21

Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth

Jun 15

Analysts Are Betting On NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) With A Big Upgrade This Week

May 09

NGM Biopharmaceuticals: How They Changed A Dead End To A Crossroad

Apr 26

Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth

Feb 21

We're Hopeful That NGM Biopharmaceuticals (NASDAQ:NGM) Will Use Its Cash Wisely

Nov 08

Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth

Jul 09

NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Annual Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Mar 06

Kazanç ve Gelir Büyüme Tahminleri

NasdaqGS:NGM - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	9	-90	-88	-46	4
12/31/2025	0	-94	-89	-78	5
12/31/2024	0	-98	-77	-69	3
12/31/2023	4	-142	-133	-132	N/A
9/30/2023	22	-151	-141	-140	N/A
6/30/2023	30	-170	-142	-141	N/A
3/31/2023	37	-178	-153	-151	N/A
12/31/2022	55	-163	-146	-144	N/A
9/30/2022	58	-153	-134	-132	N/A
6/30/2022	69	-135	-115	-114	N/A
3/31/2022	77	-125	-89	-87	N/A
12/31/2021	78	-120	-75	-73	N/A
9/30/2021	77	-121	-77	-75	N/A
6/30/2021	82	-122	-93	-91	N/A
3/31/2021	85	-111	-88	-87	N/A
12/31/2020	87	-102	-85	-83	N/A
9/30/2020	99	-90	-81	-78	N/A
6/30/2020	97	-72	-62	-60	N/A
3/31/2020	102	-54	-50	-48	N/A
12/31/2019	104	-43	-45	-41	N/A
9/30/2019	120	-13	-22	-20	N/A
6/30/2019	119	-9	-22	-19	N/A
3/31/2019	116	-5	-22	-15	N/A
12/31/2018	109	0	-13	-8	N/A
9/30/2018	81	-17	-24	-18	N/A
6/30/2018	80	-12	-22	-15	N/A
3/31/2018	77	-13	-21	-16	N/A
12/31/2017	77	-14	-24	-17	N/A
12/31/2016	86	-7	N/A	1	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: NGM önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: NGM önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: NGM önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: NGM şirketinin gelirinin (yıllık 57.6% ) US pazarından (yıllık 8.9% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: NGM şirketinin gelirinin (yıllık 57.6% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: NGM 3 yıl içinde kârsız olması bekleniyor.

NGM Biopharmaceuticals Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Consensus revenue estimates decrease by 41%, EPS upgraded

Price target decreased by 19% to US$4.83

Consensus revenue estimates fall by 26%

Consensus revenue estimates decrease by 47%, EPS upgraded

Consensus EPS estimates fall by 23%

Price target increased to US$6.20

Recent updates

NGM Biopharmaceuticals, Inc. announced that it has received $122 million in funding from The Column Group, LLC and other investors

NGM Biopharmaceuticals, Inc. announced that it has received $122 million in funding from The Column Group, LLC and other investors

NGM Biopharmaceuticals Files Form 15

The Column Group, LLC completed the acquisition of 74% stake in NGM Biopharmaceuticals, Inc. (NasdaqGS:NGM) from other group of shareholders.

The Column Group, LLC entered into a definitive Agreement to acquire 74% stake in NGM Biopharmaceuticals, Inc. (NasdaqGS:NGM) from other group of shareholders for approximately $130 million.

NGM Biopharmaceuticals to Become Privately Held Company and its Shares to be No Longer Listed on Nasdaq as Result of Closing of the Tender Offer

NGM Bio Announces New Clinical Data from Ongoing Trial of Ngm707 in Advanced Solid Tumors and Outlines Evolved Strategy for Aldafermin and Ngm120 to Focus on Rare Conditions with Significant Unmet Need

What NGM Biopharmaceuticals, Inc.'s (NASDAQ:NGM) 32% Share Price Gain Is Not Telling You

NGM Biopharmaceuticals Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement

NGM Biopharmaceuticals, Inc. Presents Positive Phase 2b Results from the Alpha 4 Trial of Aldafermin in Patients with Compensated Cirrhosis (F4) Due to NASH at AASLD The Liver Meeting

Consensus revenue estimates decrease by 41%, EPS upgraded

Price target decreased by 19% to US$4.83

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

We're A Little Worried About NGM Biopharmaceuticals' (NASDAQ:NGM) Cash Burn Rate

Ngm Biopharmaceuticals, Inc. Appoints Irene Perlich as Principal Accounting Officer, Effective September 15, 2023

NGM Biopharmaceuticals, Inc. Announces Appointment of Irene Perlich as Principal Accounting Officer, Effective September 15, 2023

Consensus revenue estimates fall by 26%

Some Analysts Just Cut Their NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Estimates

Second quarter 2023 earnings: EPS in line with expectations, revenues disappoint

Insufficient new directors

Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Could Be Quite Risky

Consensus revenue estimates decrease by 47%, EPS upgraded

First quarter 2023 earnings: EPS and revenues miss analyst expectations

NGM Biopharmaceuticals, Inc.'s (NASDAQ:NGM) Business Is Trailing The Industry But Its Shares Aren't

Consensus EPS estimates fall by 23%

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Founder exercised options and sold US$316k worth of stock

We Think NGM Biopharmaceuticals (NASDAQ:NGM) Needs To Drive Business Growth Carefully

NGM Biopharmaceuticals, Inc. Presents Preliminary Data from Phase 1 Monotherapy Dose Escalation Trial of NGM707 in Patients with Advanced or Metastatic Solid Tumors at 2022 ESMO-IO Annual Meeting

Price target increased to US$6.20

NGM Bio Announces Poster Presentation Featuring Initial Findings from Ph1a Trial of NGM707 in Patients with Advanced Solid Tumors at Upcoming 2022 ESMO-IO Annual Meeting

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Ngm Biopharmaceuticals, Inc. Announces Presentation of Post-Hoc Analyses from Catalina Phase 2 Trial of Ngm621 in Patients with Geographic Atrophy (Ga) Secondary to Age-Related Macular Degeneration At the Retina Society Annual Scientific Meeting

Lead Independent Director recently bought US$462k worth of stock

Ngm Biopharmaceuticals, Inc. (Ngm Bio) Announces Topline Efficacy and Safety Results from Its Randomized, Double-Masked, Sham-Controlled Catalina Phase 2 Trial of Ngm621 in Patients with Geographic Atrophy (Ga) Secondary to Age-Related Macular Degeneration

Price target decreased to US$28.75

NGM Biopharma sinks ~72% after phase 2 trial of its eye degeneration treatment fails

Consensus revenue estimates fall by 11%

Consensus revenue estimates fall by 22%

Second quarter 2022 earnings released: US$0.59 loss per share (vs US$0.48 loss in 2Q 2021)

Price target decreased to US$32.50

NGM Biopharmaceuticals, Inc. Announces Executive Changes

NGM Biopharmaceuticals appoints CFO Siobhan Nolan Mangini to the additional role of President

NGM Biopharmaceuticals: Eye Disorder Data Due Second Half Of 2022

Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth

NGM Biopharmaceuticals, Inc. Announces Initiation of Phase 1/1B Clinical Study of NGM438 for the Treatment of Patients with Advanced Solid Tumors

Consensus forecasts updated

Analysts Are Betting On NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) With A Big Upgrade This Week

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

NGM Biopharmaceuticals: How They Changed A Dead End To A Crossroad

NGM Biopharmaceuticals, Inc. to Present Late-Breaking Preclinical Research at 2022 AACR Annual Meeting Supporting Development of its Myeloid Reprogramming Portfolio

NGM Biopharmaceuticals, Inc., Annual General Meeting, May 18, 2022

NGM Biopharmaceuticals, Inc. Announces It Has Dosed the First Patient in A Phase 1/1B Clinical Trial of NGM831 for the Treatment of Patients with Advanced Solid Tumors

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth

CEO & Director exercised options to buy US$313k worth of stock.

Founder notifies of intention to sell stock

Founder notifies of intention to sell stock

We're Hopeful That NGM Biopharmaceuticals (NASDAQ:NGM) Will Use Its Cash Wisely

Third quarter 2021 earnings released: US$0.37 loss per share (vs US$0.43 loss in 3Q 2020)

High number of new directors

Founder notifies of intention to sell stock

Founder notifies of intention to sell stock

Price target increased to US$31.50

NGM Biopharmaceuticals, Inc. Discloses Fourth Oncology Development Candidate, NGM831, an ILT3 Antagonist Antibody, Coinciding with Publication in Cancer Immunology Research

Chief Medical Officer & Senior VP recently sold US$52k worth of stock

Founder notifies of intention to sell stock

Second quarter 2021 earnings released: US$0.48 loss per share (vs US$0.38 loss in 2Q 2020)

Consensus EPS estimates fall to -US$1.70